首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1566197

生物製藥市場規模、佔有率、成長分析，按類型、按應用、按分銷管道、按地區 - 行業預測，2024-2031

Biopharmaceuticals Market Size, Share, Growth Analysis, By Type (Vaccines, Enzymes), By Application (Cardiology, Oncology), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), By Region - Industry Forecast 2024-2031

出版日期: 2024年10月03日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球生物製藥市場規模將為2630.2億美元，從2023年的2864億美元成長到2031年的5660.8億美元，在預測期內（2024-2031年）預計複合年成長率為8.89%。

生物製藥公司向其他生物製藥公司提供包裝和藥品製造等合約服務。這將使大型生物製藥公司重新考慮其生產活動，並專注於藥物發現和行銷。許多沒有內部生產能力的中小型生技公司將灌裝和成品生產外包，以減少資本支出。生物製藥是利用生物技術製造的醫療藥物，涉及從生物來源中提取蛋白質和核酸。大多數生物藥品生物來源。基因改造生物是經過基因改造並用於生產生物製藥的動物或植物，儘管這種方法仍然存在爭議並且目前正在測試中。重組人胰島素是首批核准的治療物質之一，目前市面上有近300種生物藥。該行業的成長受到幾個關鍵因素的推動，包括人口老化、意識增強和醫療保健成本上升。此外，生物製藥新產品的核准和研發進展預計將進一步利好市場。然而，該行業面臨的主要挑戰之一是這些藥品的成本高昂，需要大幅降低成本以確保業務永續性。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Pfizer Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Services, Inc.
Bayer AG
Eli Lilly and Company
Sanofi
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
GSK plc
Takeda Pharmaceutical Company Limited
Amgen Inc.
Biogen Idec
Regeneron Pharmaceuticals, Inc.
Vertex Pharmaceuticals Inc.
Astellas Pharma Inc.
Chugai Pharmaceutical Co., Ltd.
UCB SA
Incyte Corporation

簡介目錄

Product Code: SQMIG35H2058

Global Biopharmaceuticals Market size was valued at USD 263.02 billion in 2022 and is poised to grow from USD 286.40 billion in 2023 to USD 566.08 billion by 2031, growing at a CAGR of 8.89% during the forecast period (2024-2031).

A biopharmaceutical company provides contract services to other biopharmaceutical firms, including packaging and drug manufacturing. This allows larger biopharmaceutical organizations to reevaluate their production activities, enabling them to focus on drug discovery and marketing. Many smaller biotechnology companies, lacking in-house production capacity, outsource fill and finish manufacturing to lower capital expenditures. Biopharmaceuticals are medical drugs produced using biotechnology, extracting proteins and nucleic acids from biological sources. Most biopharmaceuticals are derived from living organisms. The term ""transgenic organisms"" refers to genetically modified plants and animals, which are used in biopharmaceutical production, though this method remains contentious and is still undergoing trials. Recombinant human insulin was among the first approved therapeutic substances, and currently, nearly 300 biopharmaceutical products are available on the market. The growth of this sector is driven by several key factors, including an aging population, increased awareness, and rising healthcare costs. Additionally, ongoing research and development, along with the approval of new biopharmaceutical products, is expected to further benefit the market. However, one of the industry's major challenges is the high cost of these drugs, which needs to be significantly reduced to ensure business sustainability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceuticals market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceuticals Market Segmental Analysis

Global Biopharmaceuticals Market is segmented by Type, Application, Distribution Channel, and Region. Based on Type, the market is segmented into Immunomodulators (Monoclonal Antibodies, Cytokines, Interferons, Others), Enzymes (Hydrolases, Lyases, Oxidoreductases, Others), Vaccines (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated, Toxoid), Hormones (Human Growth Hormones, Insulin, Thyroid Stimulating Hormones, Others), Others . Based on Application, the market is segmented into Cardiology, Oncology, Respiratory, Immunology, Neurology, Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Drivers of the Global Biopharmaceuticals Market

Chronic diseases such as cancer, diabetes, and heart disease are the leading causes of death and disability globally. Biopharmaceuticals based on proteins offer effective treatments for various cancers. Key contributors to this health crisis include increased tobacco use, smoking, exposure to secondhand smoke, poor dietary habits, excessive alcohol consumption, and a sedentary lifestyle. According to the American Heart Association, cardiovascular disease (CVD) claims a life every second in the United States. Innovative biotech companies like Invizius and 3P Biopharmaceuticals have developed groundbreaking technologies for cardiovascular disease patients undergoing hemodialysis. The biopharmaceuticals market is projected to grow between 2024 and 2031 due to the rising prevalence of chronic diseases worldwide.

Restraints in the Global Biopharmaceuticals Market

Due to low incomes and the high costs of healthcare, individuals in developing nations struggle to afford biomedicines and therapies, which may hinder significant market growth during the forecast period. According to the United Nations Development Programme, as of 2023, 1.1 billion of 6.1 billion people are poor and live in poverty, limiting their access to improved healthcare facilities. The World Health Organization (WHO) reports that half of the world's population lacks access to essential medical services due to inadequate healthcare infrastructure. These challenges are adversely affecting the biopharmaceuticals market.

Market Trends of the Global Biopharmaceuticals Market

The rapid growth of the biopharmaceuticals market is largely driven by the effective use of monoclonal antibodies and their derivatives in treating conditions like cancer, rheumatoid arthritis, multiple sclerosis, and cardiovascular diseases. The COVID-19 pandemic has intensified the demand for specific monoclonal antibodies, with researchers worldwide seeking solutions to the escalating healthcare burden. Notably, the Drug Controller General of India approved Biocon Ltd.'s anti-CD6 IgG1 monoclonal antibody in July 2020 for treating cytokine release syndrome in COVID-19 patients. Additionally, FDA approvals and new product launches, such as MacroGenics' MARGENZATM and GlaxoSmithKline's BLENREP, are expected to further propel market expansion in the coming years.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Types
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Patent Analysis
Pipeline Analysis
Technology Analysis
Regulatory Landscape
Case Study Analysis
Macro-Economic Factors
PESTEL Analysis
Market Attractiveness Index, 2023

Biopharmaceuticals Market, By Type

Market Overview
Immunomodulators
- Monoclonal Antibodies
- Cytokines
- Interferons
- Others
Enzymes
- Hyrdolases
- Lyases
- Oxidoreductases
- Others
Vaccines
- Recombinant/Conjugate/Subunit
- Inactivated
- Live Attenuated
- Toxoid
Hormones
- Human Growth Hormones
- Insulin
- Thyroid Stimulating Hormones
- Others
Others

Biopharmaceuticals Market, By Application

Market Overview
Cardiology
Oncology
Respiratory
Immunology
Neurology
Others

Biopharmaceuticals Market, By Distribution Channel

Market Overview
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies

Biopharmaceuticals Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Idec
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chugai Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments